| LDR | | 00000nmm u2200205 4500 |
| 001 | | 000000332312 |
| 005 | | 20241127173731 |
| 008 | | 181129s2018 ||| | | | eng d |
| 020 | |
▼a 9780438132801 |
| 035 | |
▼a (MiAaPQ)AAI10752166 |
| 035 | |
▼a (MiAaPQ)medicine.yale:10714 |
| 040 | |
▼a MiAaPQ
▼c MiAaPQ
▼d 248032 |
| 049 | 1 |
▼f DP |
| 082 | 0 |
▼a 610 |
| 100 | 1 |
▼a Ader, Jeremy. |
| 245 | 10 |
▼a Precision Medicine in Atrial Fibrillation: A Risk Model for Management with Dabigatran v. Warfarin. |
| 260 | |
▼a [S.l.] :
▼b Yale University.,
▼c 2018 |
| 260 | 1 |
▼a Ann Arbor :
▼b ProQuest Dissertations & Theses,
▼c 2018 |
| 300 | |
▼a 75 p. |
| 500 | |
▼a Source: Dissertation Abstracts International, Volume: 79-11(E), Section: B. |
| 500 | |
▼a Adviser: Nihar R. Desai. |
| 502 | 1 |
▼a Thesis (M.D.)--Yale University, 2018. |
| 520 | |
▼a The Precision Medicine Initiative aims to advance Medicine from "one-size-fits-all" treatments to more individualized approaches. Clinical trials evaluate treatments by analyzing average outcomes, and thus risk overlooking potential differences |
| 520 | |
▼a We analyzed the Randomized Evaluation of Long-Term Anticoagulation Therapy (RELY) trial of dabigatran versus warfarin in patients with atrial fibrillation, to determine if the application of multivariate predictive models could demonstrate heter |
| 520 | |
▼a These findings demonstrate heterogeneity of treatment effect in the RE-LY trial, and the ability of multivariate risk models to identify distinct treatment risks for individual patients. Such models could be used in clinical practice provide pat |
| 590 | |
▼a School code: 0265. |
| 650 | 4 |
▼a Medicine. |
| 650 | 4 |
▼a Epidemiology. |
| 690 | |
▼a 0564 |
| 690 | |
▼a 0766 |
| 710 | 20 |
▼a Yale University.
▼b Yale School of Medicine. |
| 773 | 0 |
▼t Dissertation Abstracts International
▼g 79-11B(E). |
| 773 | |
▼t Dissertation Abstract International |
| 790 | |
▼a 0265 |
| 791 | |
▼a M.D. |
| 792 | |
▼a 2018 |
| 793 | |
▼a English |
| 856 | 40 |
▼u http://www.riss.kr/pdu/ddodLink.do?id=T14997216
▼n KERIS |
| 980 | |
▼a 201812
▼f 2019 |
| 990 | |
▼a 관리자
▼b 관리자 |